Eli Lilly Canada has advised that Strattera will be discontinued from the marketplace completely by the end of 2023. Generic atomoxetine remains available and has largely replaced the use of brand name Strattera since 2017.
Atomoxetine is a second line drug used in the treatment of ADHD. In canvassing expert opinion, there has been no significant difference noted between the brand name and generic though most experts use atomoxetine infrequently.
Long acting stimulants remain first line in the treatment of ADHD.
Information on the STRATTERA discontinuation has been posted on the Health Canada Drug Shortage website (drugshortagescanada.ca).
| Description | DIN | Anticipated Discontinuation Date |
| STRATTERA 10 mg | 02262800 | June 1, 2023 |
| STRATTERA 18 mg | 02262819 | November 1, 2023 |
| STRATTERA 25 mg | 02262827 | May 1, 2023 |
| STRATTERA 40 mg | 02262835 | March 1, 2023 |
| STRATTERA 60 mg | 02262843 | August 1, 2023 |
| STRATTERA 80 mg | 02279347 | December 1, 2023 |
| STRATTERA 100 mg | 02279355 | April 3, 2023 |